alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
#### § 1308.32 Exempted prescription products.

The compounds, mixtures, or preparations that contain a nonnarcotic controlled substance listed in § 1308.12(e) or in § 1308.13(b) or (c) or in § 1308.14 or in § 1308.15 listed in the Table of Exempted Prescription Products have been exempted by the Administrator from the application of sections 302 through 305, 307 through 309, and 1002 through 1004 of the Act (21 U.S.C. 822-825, 827-829, and 952-954) and §§ 1301.13, 1301.22, and §§ 1301.71 through 1301.76 of this chapter for administrative purposes only. An exception to the above is that those products containing butalbital shall not be exempt from the requirement of 21 U.S.C. 952-954 concerning importation, exportation, transshipment and in-transit shipment of controlled substances. Any deviation from the quantitative composition of any of the listed drugs shall require a petition of exemption in order for the product to be exempted. A listing of the Exempted Prescription Products may be obtained by submitting a written request to the Drug and Chemical Evaluation Section, Drug Enforcement Administration. See the Table of DEA Mailing Addresses in § 1321.01 of this chapter for the current mailing address.

[75 FR 10679, Mar. 9, 2010]
Exhibit



 
Execution Version



Third Amendment
to
Master Services Agreement


The Master Services Agreement dated as of November 29, 2007, consisting of the terms and conditions set forth therein and the attached schedules, all as previously amended, (the “Agreement”) by and between Graphic Packaging International, Inc. (“GPI”) and Perot Systems Corporation is hereby amended effective as of November 1, 2016 (“Third Amendment Effective Date”) by this Third Amendment (“Third Amendment”).  The Parties to this Third Amendment are GPI and Dell Marketing L.P. (“Dell”) (as assignee of Perot Systems Corporation).  Capitalized terms used without definition in this Third Amendment have the meanings provided in the Agreement.  
In consideration of the terms and conditions of this Third Amendment and the Agreement, and for other good and valuable consideration, the receipt and sufficiency of which the Parties acknowledge, the Parties agree as follows:
		
	1.
	Schedules and Attachments. 


The following Schedules to the Agreement, including the Attachments to the following Schedules, are amended and restated, effective as of the Third Amendment Effective Date and, as so amended and restated, are attached to and a part of this Third Amendment.
Schedule 1.1(a) Service Recipients
Schedule 2.1.1 Service Towers
Schedule 2.10 Service Level Agreement
Schedule 4.1 Charges
Schedule 8.2 Financial Responsibilities Matrix
Schedule 9.2(a)(i)(B) GPI Competitors
Schedule 9.3(b) Consented Subcontractors
Schedule 10.2 Service Locations
Schedule 15.1 Termination Fees
		
	2.
	Effect of Amendment.


In the event of any conflict or inconsistency between the terms and conditions of this Third Amendment and those of the Agreement, the terms and conditions of this Third Amendment shall control to the extent of such conflict or inconsistency.  All other terms and conditions in the Agreement not amended by this Third Amendment shall remain in full force and effect.
IN WITNESS WHEREOF, the Parties have duly executed and delivered this Third Amendment as of the date(s) set forth below.


	
		
	GRAPHIC PACKAGING INTERNATIONAL, INC. 
By:      
Name:   
Title:   
Date:   
	DELL MARKETING L.P. 
By:      
Name:   
Title:   
Date:   












- 1 -
<PAGE>   1
                                                                    Exhibit 23.2




                         CONSENT OF INDEPENDENT AUDITORS


The Board of Directors
VaxGen, Inc.:


We consent to the use of our report included herein and to the reference to our
firm under the heading "Experts" in the prospectus.

/s/ KPMG LLP


Seattle, Washington
May 5, 1999
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               JUN-30-1997
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                  217,973
<ALLOWANCES>                                         0
<INVENTORY>                                  3,474,990
<CURRENT-ASSETS>                            12,299,269
<PP&E>                                       6,278,088
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              18,945,255
<CURRENT-LIABILITIES>                       10,922,909
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       425,288
<OTHER-SE>                                   7,597,058
<TOTAL-LIABILITY-AND-EQUITY>                18,945,255
<SALES>                                     30,718,640
<TOTAL-REVENUES>                            30,718,640
<CGS>                                       15,773,814
<TOTAL-COSTS>                               29,321,355
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              1,621,149
<INCOME-TAX>                                   580,000
<INCOME-CONTINUING>                          1,041,149
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 1,041,149
<EPS-PRIMARY>                                     0.23
<EPS-DILUTED>                                     0.23
        

</TABLE>
<PAGE>
                                                                      Exhibit 21

<TABLE>
<CAPTION>

       SUBSIDIARY                                     PLACE OF INCORPORATION
       ----------                                     ----------------------
<S>                                                          <C>
Clare Capital, Inc.                                           Delaware
Clare Components, Inc.                                        Delaware
Clare Electronics, Inc.                                       Delaware
Clare Instruments, Inc.                                       Delaware
Clare Services, Inc.                                          Delaware
Clare Systems, Inc.                                           Delaware
Clare Technologies, Inc.                                      Delaware
Clare Canada, Ltd.                                            Ontario, Canada
Clare France S. A. R. L.                                      France
C.P. Clare Electronics GmbH                                   Germany
C.P. Clare Foreign Sales Corporation                          U.S. Virgin Islands
C.P. Clare International N.V.                                 Belgium
C.P. Clare Mexicana S.A. de C.V.                              Mexico
Clare Technologies (Taiwan), Inc.                             Taiwan
</TABLE>
**EXHIBIT
      32.2**








**CERTIFICATION
      PURSUANT TO**


**18
      U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO**


**SECTION 906
      OF THE SARBANES-OXLEY ACT OF 2002**








In
      connection with the accompanying Quarterly Report on Form 10-Q of Southwall
      Technologies Inc. (the “Company”), for the quarter ended July 3, 2005, as filed
      with the Securities and Exchange Commission on the date hereof (the “Report”),
      I, Sylvia Kamenski, the Acting Chief Financial Officer of the Company, hereby
      certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
      Section 906 of the Sarbanes-Oxley Act of 2002, that:





1)
            the
                Report fully complies with the requirements of Section 13(a) or 15(d)
                of
                the Securities Exchange Act of 1934;
                and




2)
            the
                information contained in the Report fairly presents, in all material
                respects, the financial condition and results of operations of the
                Company.




August
                5, 2005
            By:
            /s/
                Sylvia KamenskiSylvia Kamenski*Acting
                Chief Financial Officer*








A
      signed
      original of this written statement required by Section 906, or other
      document authenticating, acknowledging or otherwise adopting the signature
      that
      appears in typed form within the electronic version of this written statement
      required by Section 906, has been provided to the Company and will be
      retained by the Company and furnished to the Securities and Exchange Commission
      or its staff upon request.





In
      accordance with Item 601 of Regulation S-K, this certification is being
“furnished” as Exhibit 32.2 to the Company's quarterly report and shall not
      be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
      of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that
      section, nor shall it be deemed incorporated by reference in any filing under
      the Securities Act of 1933 or the Exchange Act, except as expressly set forth
      by
      specific reference in such a filing.
I 

118TH CONGRESS 

2D SESSION H. R. 7143 

To require the heads of certain agencies to withdraw a proposed rule relating 

to capital requirements applicable to large banking organizations and 

banking organizations with significant trading activity, and for other 

purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 30, 2024 

Mr. OGLES (for himself and Mr. DONALDS) introduced the following bill; 

which was referred to the Committee on Financial Services 

A BILL 

To require the heads of certain agencies to withdraw a proposed rule relating to capital requirements applicable 

to large banking organizations and banking organizations 

with significant trading activity, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Stop Basel Endgame 

5 Act’’. 

6 SEC. 2. WITHDRAWAL OF REGULATORY CAPITAL RULE. 

7 (a) IN GENERAL.—The head of each covered agen8 cy— 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7143 IH

1 (1) shall withdraw the proposed rule entitled 

2 ‘‘Regulatory Capital Rule: Large Banking Organiza3 tions and Banking Organizations with Significant 

4 Trading Activity’’ (88 Fed. Reg. 64028); and 

5 (2) may not take any action to finalize, imple6 ment, or enforce the proposed rule described in 

7 paragraph (1) or any substantially similar rule. 

8 (b) COVERED AGENCY DEFINED.—For purposes of 

9 this section, the term ‘‘covered agency’’ means each of the 

10 following Federal agencies: 

11 (1) The Office of the Comptroller of the Cur12 rency. 

13 (2) The Federal Reserve System. 

14 (3) The Federal Deposit Insurance Corporation. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
<PAGE>   1




                                                                      EXHIBIT 11




Statement Regarding Computation of Earnings Per Share

(in 000's, except per share amounts)
                                    Three Months Ended        Nine Months Ended

                                     Sept. 30,  Oct.2,       Sept. 30,  Oct. 2,
                                       2000      1999          2000      1999

Weighted average shares outstanding   47,248   48,200         47,250    48,422

Effect of dilutive securities             67      464             86       823

Shares for diluted EPS                47,315   48,664         47,336    49,245


Net income (loss)                    $(3,973) $(5,921)       $   150   $44,458



Per share amounts:

  Basic                              $ (0.08) $ (0.12)       $  0.00   $  0.92


  Diluted                            $ (0.08) $ (0.12)       $  0.00   $  0.90
<PAGE>

                                                                  EXHIBIT 10.9.2


                             SECOND AMENDMENT TO THE

                       REVOLVING LINE OF CREDIT AGREEMENT

This SECOND AMENDMENT ("Amendment") is dated as of May 23, 2000, by and between
WFS FINANCIAL INC, a California corporation ("WFS"), and WESTERN FINANCIAL BANK,
a federally-chartered savings bank (the "Bank"), and amends the REVOLVING LINE
OF CREDIT AGREEMENT ("Agreement") entered into by the parties on June 15, 1999,
pursuant to the transfer of certain assets of the Bank to WFS.

                                    RECITALS

A.       The Agreement is being amended to reflect differing interest spreads.

B.       The Agreement is being amended to reflect changes in the maximum amount
of credit available as set out in Section 2.1.1

C.       Notification of the proposed increase was made to the Office of Thrift
Supervision ("OTS"), the regulatory agency for the Bank, pursuant to a
requirement from the OTS dated June 5, 1995, to advise the OTS of any proposals
to amend the Agreement which would materially revise the information on which
the OTS based its initial approval of establishing the Line of Credit.

                                    AGREEMENT

         In consideration of the mutual promises set forth herein, and in
reliance upon the recitals set forth above, the parties agree as follows:

   1.       CERTAIN DEFINITIONS

            The definition of "INTEREST SPREAD" is hereby amended as follows:

            "INTEREST SPREAD" shall mean (1) 125 basis points over LIBOR for
unsecured borrowings and, (2) 75 basis points over LIBOR for secured borrowings.

   2.1.1.   COMMITMENT

            Section 2.1.1 of the Agreement is amended to increase the aggregate
sum owing at any one time from $1,300,000,000 to $1,800,000,000.

      Except as specifically amended herein, all terms of the Agreement as
previously amended shall remain in full force and effect. Wherefore, the
undersigned have executed this Amendment on the date set forth below to be
effective as of the date first set forth above.

WFS FINANCIAL INC                         WESTERN FINANCIAL BANK


______________________________            ________________________________
Thomas A. Wolfe, President and            Lee A. Whatcott,
Chief Operating Officer                   Senior Executive Vice President
                                          and Chief Financial Officer

May 23, 2000
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Dental and Craniofacial Research Special Emphasis Panel; Review of R21 ONJ applications (PAR-06-556).                    

*Date:*                         February 11, 2010.                    

*Time:*                         1 p.m. to 4 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).                     

*Contact Person:*                         Lynn M. King, PhD, Chief, Scientific Review Branch, National Institute of Dental and Craniofacial Research/NIH, 6701 Democracy Blvd., Bethesda, MD 20892-6402, 301-594-5006,                         *lynn.king@nih.gov*.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

Dated: December 30, 2009.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-39 Filed 1-13-10; 8:45 am]

BILLING CODE 4140-01-P
* Pursuant to 5 TH C IR . R. 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. United States Court of Appeals Fifth Circuit 

## FILED October 21, 2004 Charles R. Fulbruge III Clerk IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 04-50385 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus JOSE AVILES-JAIMES, also known as Jose Aviles, Defendant-Appellant.

-------------------- Appeal from the United States District Court for the Western District of Texas USDC No. 1:04-CR-12-ALL-SS

-------------------- Before JOLLY, JONES, and WIENER, Circuit Judges.
PER CURIAM: *Appealing the Judgment in a Criminal Case, Jose AvilesJaimes concedes that the arguments raised are foreclosed by circuit precedent but seeks to preserve them for further review. The Government has moved for summary affirmance in lieu of filing an appellee’s brief. The motion is GRANTED, and the judgment of the district court is AFFIRMED.
<PAGE>
 
                                                                      EXHIBIT 11

                              Mycogen Corporation
                                  Exhibit 11
                Statements re Computation of Per Share Earnings
                 (Amounts in thousands, except per share data)
<TABLE> 
<CAPTION> 
                                                         Three months ended May 31,        Nine months ended May 31,
                                                             1997         1996               1997          1996
                                                         ----------    -----------         ---------    -----------
<S>                                                      <C>           <C>                 <C>          <C>
Net income (loss) applicable to common shares..........  $      564    $     3,521         $  (6,981)   $  (28,819)
                                                         ==========    ===========         =========    ==========

Weighted average number of shares outstanding:
Average common shares..................................      30,943         30,575            30,827        24,816

Stock option equivalent shares.........................       2,287          1,759                --(1)         --(1)
                                                         ----------    -----------         ---------    ----------
Average common shares for computation of primary net
 income (loss) per common share........................      33,230(2)      32,334            30,827        24,816

Additional stock option equivalent shares..............         130             81                --(1)         --(1)
                                                         ----------    -----------         ---------    ----------
Average shares for computation of net income (loss)
 per common share assuming full dilution...............      33,360(2)      32,415            30,827        24,816
                                                         ==========    ===========         =========    ==========

Net income (loss) per common share:
 Primary...............................................  $      .02    $       .11         $    (.23)   $    (1.16)
                                                         ==========    ===========         =========    ==========

 Assuming full dilution...............................   $      .02    $       .11         $    (.23)   $    (1.16)
                                                         ==========    ===========         =========    ==========
</TABLE> 

(1) Additional shares from stock option equivalents were not included in the
calculation of net income (loss) per common share where the effect was 
antidilutive.

(2) This calculation is submitted in accordance with Securities Exchange Act of
1934 Release No. 9083 although not required by footnote 2 to paragraph 14 of APB
Opinion No. 15 because it results in dilution of less than 3%.
<PAGE>   1

                                                                    EXHIBIT 23.1


                    CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS



        As independent public accountants, we hereby consent to the
incorporation of our reports included in this Form 10-K into the Company's
previously filed Registration Statements (Form S-8, No. 33-75570 and Forms S-3,
No. 333-2258 and No. 333-21913).


                                             ARTHUR ANDERSEN LLP

        Portland, Oregon
        September 24, 1999
EXHIBIT 32

                            CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


<PAGE>

EXHIBIT 32


                            CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


     In connection  with the Quarterly  Report of Momentum  Biofuels,  Inc. (the
"Company") on Form 10-QSB for the period ending March 31, 2008 as filed with the
Securities and Exchange Commission on the date hereof (the "Report"). I, Gregory
A. Enders, President of the company,  certify,  pursuant to 18 USC Section 1350,
as adopted  pursuant to Section 906 of the  Sarbanes-Oxley  Act of 2002, that to
the best of my knowledge and belief.

        (1)     The Report fully complies with the requirements of Section 13(a)
                or 15(d) of the Securities Exchange Act of 1934; and

        (2)     The information  contained in the Report fairly presents, in all
                material  respects,  the  financial  condition  and  results  of
                operations of the Company.


                                         /s/ Gregory A. Enders
                                         --------------------------------
                                         Gregory A. Enders, President
Date: May 20, 2008